Evidence map›Paper›PMID 26433932›Full record

ArticleHuman molecular genetics2015

APP overexpression in the absence of NPC1 exacerbates metabolism of amyloidogenic proteins of Alzheimer's disease.

Mahua Maulik, Kyle Peake, JiYun Chung, Yanlin Wang, Jean E Vance, Satyabrata Kar

Abstract read
In one paragraph

Article in Human molecular genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Understanding and Treating Niemann-Pick Type C Disease: Models Matter.International journal of molecular sciences · 2020
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Mahua MaulikCentre for Prions and Protein Folding Diseases, Centre for Neuroscience, Department of Medicine, and.
Kyle PeakeDepartment of Medicine, and.
JiYun ChungCentre for Prions and Protein Folding Diseases, Department of Psychiatry, University of Alberta, Edmonton, AB T6G 2M8, Canada.
Yanlin WangCentre for Prions and Protein Folding Diseases, Department of Psychiatry, University of Alberta, Edmonton, AB T6G 2M8, Canada.
Jean E VanceDepartment of Medicine, and.
Satyabrata KarCentre for Prions and Protein Folding Diseases, Centre for Neuroscience, Department of Medicine, and Department of Psychiatry, University of Alberta, Edmonton, AB T6G 2M8, Canada skar@ualberta.ca.
University of Alberta · CAInstitut des Sciences Cognitives Marc Jeannerod · FR

Funding

Canadian Institutes of Health Research MOP-123258
6 · The paper itself

Abstract

Amyloid-β (Aβ) peptides originating from β-amyloid precursor protein (APP) are critical in Alzheimer's disease (AD). Cellular cholesterol levels/distribution can regulate production and clearance of Aβ peptides, albeit with contradictory outcomes. To better understand the relationship between cholesterol homeostasis and APP/Aβ metabolism, we have recently generated a bigenic ANPC mouse line overexpressing mutant human APP in the absence of Niemann-Pick type C-1 protein required for intracellular cholesterol transport. Using this unique bigenic ANPC mice and complementary stable N2a cells, we have examined the functional consequences of cellular cholesterol sequestration in the endosomal-lysosomal system, a major site of Aβ production, on APP/Aβ metabolism and its relation to neuronal viability. Levels of APP C-terminal fragments (α-CTF/β-CTF) and Aβ peptides, but not APP mRNA/protein or soluble APPα/APPβ, were increased in ANPC mouse brains and N2a-ANPC cells. These changes were accompanied by reduced clearance of peptides and an increased level/activity of γ-secretase, suggesting that accumulation of APP-CTFs is due to decreased turnover, whereas increased Aβ levels may result from a combination of increased production and decreased turnover. APP-CTFs and Aβ peptides were localized primarily in early-/late-endosomes and to some extent in lysosomes/autophagosomes. Cholesterol sequestration impaired endocytic-autophagic-lysosomal, but not proteasomal, clearance of APP-CTFs/Aβ peptides. Moreover, markers of oxidative stress were increased in vulnerable brain regions of ANPC mice and enhanced β-CTF/Aβ levels increased susceptibility of N2a-ANPC cells to H2O2-induced toxicity. Collectively, our results show that cellular cholesterol sequestration plays a key role in APP/Aβ metabolism and increasing neuronal vulnerability to oxidative stress in AD-related pathology.

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAmyloidogenic ProteinsAnimalsAutophagyCell Line, TumorCell SurvivalCholesterolEndosomesHumansIntracellular Signaling Peptides and ProteinsLysosomesMiceMice, Inbred C57BLMutationNeuronsAmyloid beta-Protein PrecursorAmyloidogenic ProteinsCholesterolIntracellular Signaling Peptides and ProteinsNiemann-Pick C1 ProteinNpc1 protein, mouseProteasome Endopeptidase ComplexProteins

Identifiers

PMID26433932
PMCPMC4654063
OpenAlexW2176836693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.